{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:45:42Z","timestamp":1789505142403,"version":"build-2803163510"},"reference-count":9,"publisher":"Japanese Urological Association","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn. j. urol"],"published-print":{"date-parts":[[2015]]},"DOI":"10.5980\/jpnjurol.106.30","type":"journal-article","created":{"date-parts":[[2016,1,19]],"date-time":"2016-01-19T22:23:47Z","timestamp":1453242227000},"page":"30-34","source":"Crossref","is-referenced-by-count":1,"title":["PATHOLOGICAL COMPLETE RESPONSE WITH EVEROLIMUS FOR MULTIPLE LUNG METASTASES OF RENAL CELL CARCINOMA RESISTANT TO SUNITINIB"],"prefix":"10.5980","volume":"106","author":[{"given":"Kazuhiro","family":"Namura","sequence":"first","affiliation":[{"name":"Department of Urology, Yokohama Municipal Citizen's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Otake","sequence":"additional","affiliation":[{"name":"Department of Urology, Yokohama Municipal Citizen's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Sawada","sequence":"additional","affiliation":[{"name":"Department of Urology, Yokohama Municipal Citizen's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Fujikawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Yokohama Municipal Citizen's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Ota","sequence":"additional","affiliation":[{"name":"Department of Urology, Yokohama Municipal Citizen's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Moriyama","sequence":"additional","affiliation":[{"name":"Department of Urology, Yokohama Municipal Citizen's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4001","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A and Ferrara J: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol, 17 (8), 2530-2540, 1999.","DOI":"10.1200\/JCO.1999.17.8.2530"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Escudier B, Eisen T, Porta C, Patard JJ, Khoo V, Algaba F, Mulders P and Kataja V; on behalf of the ESMO Guidelines Working Group: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 23(Suppl 7), 65-71, 2012.","DOI":"10.1093\/annonc\/mds227"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Tomita Y, Shinohara N, Yuasa T, Fujimoto H, Niwakawa M, Mugiya S, Miki T, Uemura H, Nonomura N, Takahashi M, Hasegawa Y, Agata N, Houk B, Naito S and Akaza H: Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol, 40(12), 1166-1172, 2010.","DOI":"10.1093\/jjco\/hyq146"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4) Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Gr\u00fcnwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D and Ravaud A: RECORD-1 Study Group: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial. Lancet, 372, 449-456, 2008.","DOI":"10.1016\/S0140-6736(08)61039-9"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Tsukamoto T, Shinohara N, Hamamoto Y, Maruoka M, Fujimoto H, Niwakawa M, Uemura H, Usami M, Terai A, Kanayama HO, Sumiyoshi Y, Eto M and Akaza H: Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. Jpn J Clin Oncol, 41 (1), 17-24, 2011.","DOI":"10.1093\/jjco\/hyq166"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Mizuno R, Asano K, Mikami S, Nagata H, Kaneko G and Oya M: Patterns of Interstitial Lung Disease During Everolimus Treatment in Patients with Metastatic Renal Cell Carcinoma. Jpn J Clin Oncol, 42 (5), 442-446, 2012.","DOI":"10.1093\/jjco\/hys033"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Iwasaki K, Obara W and Fujioka T: Case of complete response to everolimus for metastatic renal cell carcinoma. Int J Urol, 19(9), 891-892, 2012.","DOI":"10.1111\/j.1442-2042.2012.03039.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Gr\u00fcnwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N and Bodrogi I; REACT Study Group: An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Eur J Cancer, 48(3), 324-332, 2012.","DOI":"10.1016\/j.ejca.2011.06.054"},{"key":"9","unstructured":"10) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Kidney Cancer, Version2. 2014, 2014."}],"container-title":["The Japanese Journal of Urology"],"original-title":["\u30a8\u30d9\u30ed\u30ea\u30e0\u30b9\u306b\u3066\u75c5\u7406\u5b66\u7684\u5b8c\u5168\u594f\u52b9\u3068\u306a\u3063\u305f\u30b9\u30cb\u30c1\u30cb\u30d6\u62b5\u6297\u6027\u814e\u764c\u80ba\u8ee2\u79fb\u306e1\u4f8b"],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/106\/1\/106_30\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T20:52:52Z","timestamp":1567543972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/106\/1\/106_30\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.5980\/jpnjurol.106.30","relation":{},"ISSN":["0021-5287","1884-7110"],"issn-type":[{"value":"0021-5287","type":"print"},{"value":"1884-7110","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}